Slack N H, Mittelman A, Brady M F, Murphy G P
Cancer. 1980 Dec 1;46(11):2393-402. doi: 10.1002/1097-0142(19801201)46:11<2393::aid-cncr2820461115>3.0.co;2-6.
Categories of objective response to chemotherapy for 460 advanced relapsing prostate cancer patients evaluated in the initial first four randomized clinical trials of the National Prostatic Cancer Project were compared by survival and other patient and disease characteristics. The response criteria for stable were shown to delineate patients with markedly improved survival and other disease conditions relative to those designated as progression. Survival was similar for stable and partial regression patients despite more frequent reduction of primary tumor and subjective improvement in performance status, pain, and body weight in the partial regression patients. Consequently, we feel that in these studies the stable category is valid and useful for determining efficacy of treatment in patients with advancing prostate cancer.
通过生存情况以及其他患者和疾病特征，对在国家前列腺癌项目最初的四项随机临床试验中评估的460例晚期复发性前列腺癌患者化疗客观反应的类别进行了比较。结果显示，稳定的反应标准所界定的患者，相对于那些被指定为疾病进展的患者，其生存情况以及其他疾病状况有显著改善。尽管部分缓解患者的原发肿瘤更频繁缩小，且其体能状态、疼痛和体重有主观改善，但稳定和部分缓解患者的生存情况相似。因此，我们认为在这些研究中，稳定类别对于确定晚期前列腺癌患者的治疗疗效是有效且有用的。
